News | March 09, 2022
SII’s Covovax approved for 12-17 years age group
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
A simple blood test detects over 30 types of cancers
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Subscribe To Our Newsletter & Stay Updated
